CF Plus Chemicals at the conference PEGS 2019 in Lisbon

CF Plus Chemicals was presenting its novel, patent-pending technology (CF LINK) for protein bioconjugation at the Protein and Antibody Engineering Summit (PEGS) in Lisbon.

Dr. Václav Matoušek, CEO and founder of the company explained in his talk in the section Next-Generation Antibody Drug Conjugates (ADC) how the bioconjugation protocol based on hypervalent iodine-fluoroalkyl reagents (2nd generation of Togni reagents) can be used not only to achieve tryptophan-selective bioconjugation but also to perform posttranslational modification of proteins such as insulin. Besides applications in protein bioconjugation, he demonstrated that the ultrarapid nature of the protein functionalization can be transformed into a powerful tool for structural proteomics and the study of protein-protein interactions.

More about the technology: https://www.uochb.cz/en/news/142/new-technology-cf-link-for-protein-bioconjugation-and-structural-proteomics